Business - Briefly   

Merck Specialities launches cancer drug

CHENNAI: Merck Specialities Pvt. Ltd., the Indian subsidiary of Merck KGaA, on Friday announced the introduction of Erbitux, a new gold standard targeted therapy for the treatment of colorectal cancer (CRC) in India. Erbitux, which has already obtained approval for the treatment of CRC in 53 countries, is a significant step forward in the management of cancer in India, says a company release.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Russia threatens U.S. with trade war
Stone laid for TAPP's facility
Sensex snaps 7-day gaining streak
Qualcomm acquires Qualphone for $18 m
State Bank hikes deposit rates
Essar to revamp businesses
PepsiCo ready for independent testing of pesticide residue
M&M launches Scorpio range in Sri Lanka
SIB launches products for NRIs, returnees
Kerala can attract major investments: Worbus Capital
Rupee ends lower
Exchange rates
Bullion rates
Inflation rate rises to 4.82 p.c.
Roongta is SAIL Chairman
'Excise exemption only for HP, Uttaranchal'
Govt. modifies 3CD tax form
China to cut tarrifs
Airtel Broadband introduces India PCO
Merck Specialities launches cancer drug
Hero Honda bags award
TV 18 promoter sells shares to Network 18
Balrampur Chini to acquire stake in Indo Gulf Ind.
Enam to venture into insurance broking

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu